{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:40:32Z","timestamp":1784860832798,"version":"3.55.0"},"reference-count":60,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:p>Thyroid nodules are extremely common with a prevalence of up to 70% in the general population. While the majority of these are benign, 5\u201310% harbor a malignancy. Fine-needle aspiration has been widely implemented to stratify the cancer risk of thyroid nodules. Standardized diagnoses using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) have aided in the triaging of nodules. While many cases are categorized with a definite diagnosis of benign (Bethesda II) or malignant (Bethesda VI) results, approximately 25% of cases are diagnosed as atypia of undetermined significance (AUS) (Bethesda III) or follicular neoplasm (Bethesda IV). These cytological categories imply an intermediate risk of malignancy ranging from 16 to 48%. These nodules, collectively defined as indeterminate thyroid nodules, pose diagnostic and management challenges. In recent years, several commercial molecular testing (MT) methods have become available to improve risk stratification, successfully helping to reduce unnecessary surgeries. In this review, we provide an overview of MT methods, present practical guidance on interpreting test results, and conclude with a discussion on future directions in the field.<\/jats:p>","DOI":"10.1530\/erc-25-0258","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:52:11Z","timestamp":1769698331000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Molecular testing for the management of indeterminate thyroid nodules"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0720-1302","authenticated-orcid":true,"given":"Irina","family":"Azaryan","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Maxwell","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5790-4894","authenticated-orcid":true,"given":"Danielle H","family":"Tran","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Sipos","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Endo","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026070909444917200_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/thy.2012.0011","article-title":"Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature","volume":"22","author":"Giordano","year":"2012","journal-title":"Thyroid"},{"key":"2026070909444917200_bib5","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/cam4.3747","article-title":"The quality of life in papillary thyroid microcarcinoma patients undergoing lobectomy or total thyroidectomy: a cross-sectional study","volume":"10","author":"Lan","year":"2021","journal-title":"Cancer Med"},{"key":"2026070909444917200_bib6","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1245\/s10434-019-07786-x","article-title":"Levothyroxine supplementation following hemithyroidectomy: incidence, risk factors, and characteristics","volume":"26","author":"Ahn","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2026070909444917200_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-159-5-201309030-00006","article-title":"A prospective assessment defining the limitations of thyroid nodule pathologic evaluation","volume":"159","author":"Cibas","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026070909444917200_bib2","first-page":"1039","article-title":"The 2023 bethesda system for reporting thyroid cytopathology","volume":"33","author":"Ali","year":"2023","journal-title":"Thyroid"},{"key":"2026070909444917200_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070909444917200_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1309\/AJCP4P2GCCDNHFMY","article-title":"Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach?","volume":"135","author":"VanderLaan","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"2026070909444917200_bib10","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/thy.2013.0317","article-title":"Malignancy rate in thyroid nodules classified as Bethesda category III (AUS\/FLUS)","volume":"24","author":"Ho","year":"2014","journal-title":"Thyroid"},{"key":"2026070909444917200_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2026070909444917200_bib12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1089\/thy.2019.0278","article-title":"Molecular variants and their risks for malignancy in cytologically indeterminate thyroid nodules","volume":"29","author":"Goldner","year":"2019","journal-title":"Thyroid"},{"key":"2026070909444917200_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070909444917200_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hurthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"key":"2026070909444917200_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"key":"2026070909444917200_bib16","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1210\/jc.2009-0247","article-title":"Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules","volume":"94","author":"Nikiforov","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070909444917200_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1089\/thy.2015.0049","article-title":"Performance of the Afirma gene expression classifier in hurthle cell thyroid nodules differs from other indeterminate thyroid nodules","volume":"25","author":"Brauner","year":"2015","journal-title":"Thyroid"},{"key":"2026070909444917200_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12918-019-0693-z","article-title":"Identification of Hurthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms","volume":"13","author":"Hao","year":"2019","journal-title":"BMC Syst Biol"},{"key":"2026070909444917200_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/thy.2019.0088","article-title":"Short review: genomic alterations in Hurthle cell carcinoma","volume":"29","author":"Ganly","year":"2019","journal-title":"Thyroid"},{"key":"2026070909444917200_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"key":"2026070909444917200_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"2026070909444917200_bib23","article-title":"Histopathology of telomerase reverse transcriptase promoter (TERT) mutated indeterminate thyroid nodules","volume":"35","author":"Pinto","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070909444917200_bib24","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1210\/clinem\/dgae134","article-title":"Analytical validation of a telomerase reverse transcriptase (TERT) promoter mutation assay","volume":"109","author":"Iyer","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/cncy.22744","article-title":"Combined Afirma genomic sequencing classifier and TERT promoter mutation detection in molecular assessment of Bethesda III\u2013VI thyroid nodules","volume":"131","author":"Ladenson","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"2026070909444917200_bib26","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/clinem\/dgac688","article-title":"Real-world performance of the Afirma genomic sequencing classifier (GSC)-A meta-analysis","volume":"108","author":"Nasr","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-15-1163","article-title":"Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests","volume":"174","author":"Valderrabano","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2026070909444917200_bib28","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1210\/clinem\/dgae112","article-title":"Outcomes of cytologically indeterminate thyroid nodules managed with genomic sequencing classifier","volume":"109","author":"Ahmadi","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/cen.13747","article-title":"Outcomes of Bethesda categories III and IV thyroid nodules over 5 years and performance of the Afirma gene expression classifier: a single-institution study","volume":"89","author":"Deaver","year":"2018","journal-title":"Clin Endocrinol"},{"key":"2026070909444917200_bib30","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1210\/clinem\/dgad181","article-title":"Bethesda III and IV thyroid nodules managed nonoperatively after molecular testing with Afirma GSC or Thyroseq v3","volume":"108","author":"Kim","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jc.2011-1469","article-title":"Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples","volume":"96","author":"Nikiforov","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/cncr.31245","article-title":"Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules","volume":"124","author":"Nikiforova","year":"2018","journal-title":"Cancer"},{"key":"2026070909444917200_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2022.103394","article-title":"Diagnostic performance of the second-generation molecular tests in the assessment of indeterminate thyroid nodules: a systematic review and meta-analysis","volume":"43","author":"Lee","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"2026070909444917200_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncy.22362","article-title":"ThyroSeq v3 for Bethesda III and IV: an institutional experience","volume":"129","author":"Desai","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"2026070909444917200_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/thy.2024.0455","article-title":"Thyroid nodules with indeterminate cytology and negative molecular profile: prevalence of malignancy and practice paradigms for surveillance","volume":"35","author":"Nachum","year":"2025","journal-title":"Thyroid"},{"key":"2026070909444917200_bib62","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2015-1158","article-title":"Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology","volume":"100","author":"Labourier","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib36","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/dc.24564","article-title":"Multiplatform molecular test performance in indeterminate thyroid nodules","volume":"48","author":"Lupo","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"2026070909444917200_bib37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncy.22829","article-title":"The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in indeterminate thyroid nodules: a large, blinded, real-world, observational study","volume":"132","author":"Verma","year":"2024","journal-title":"Cancer Cytopathol"},{"key":"2026070909444917200_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","article-title":"Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial","volume":"7","author":"Livhits","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026070909444917200_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncy.22439","article-title":"Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hurthle cell (oncocytic) type","volume":"129","author":"Landau","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"2026070909444917200_bib40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/cncr.27770","article-title":"Hurthle cell carcinoma: a population-level analysis of 3311 patients","volume":"119","author":"Goffredo","year":"2013","journal-title":"Cancer"},{"key":"2026070909444917200_bib41","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/thy.2016.0246","article-title":"Radioactive iodine treatment is associated with improved survival for patients with Hurthle cell carcinoma","volume":"26","author":"Jillard","year":"2016","journal-title":"Thyroid"},{"key":"2026070909444917200_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0726","article-title":"Independent comparison of the Afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules","volume":"29","author":"Angell","year":"2019","journal-title":"Thyroid"},{"key":"2026070909444917200_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/thy.2018.0733","article-title":"Afirma gene sequencing classifier compared with gene expression classifier in indeterminate thyroid nodules","volume":"29","author":"Endo","year":"2019","journal-title":"Thyroid"},{"key":"2026070909444917200_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4158\/EP-2018-0395","article-title":"Statistical comparison of Afirma Gsc and Afirma Gec outcomes in a community endocrine surgical practice: early findings","volume":"25","author":"Harrell","year":"2019","journal-title":"Endocr Pract"},{"key":"2026070909444917200_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jasc.2021.07.002","article-title":"Performance of Afirma gene sequencing classifier versus gene expression classifier in thyroid nodules with indeterminate cytology","volume":"11","author":"Yang","year":"2022","journal-title":"J Am Soc Cytopathol"},{"key":"2026070909444917200_bib46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.surg.2023.05.046","article-title":"Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hurthle cell cytology","volume":"175","author":"Raghunathan","year":"2024","journal-title":"Surgery"},{"key":"2026070909444917200_bib47","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cncr.33421","article-title":"Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study","volume":"127","author":"Yip","year":"2021","journal-title":"Cancer"},{"key":"2026070909444917200_bib48","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1089\/thy.2022.0282","article-title":"Performance of a multigene genomic classifier in thyroid nodules with suspicious for malignancy cytology","volume":"32","author":"Skaugen","year":"2022","journal-title":"Thyroid"},{"key":"2026070909444917200_bib49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoto.2023.1494","article-title":"Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda V) or known (Bethesda VI) papillary thyroid cancer","volume":"149","author":"Schumm","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026070909444917200_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.surg.2022.05.048","article-title":"Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes","volume":"173","author":"Liu","year":"2023","journal-title":"Surgery"},{"key":"2026070909444917200_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/jpm13010024","article-title":"Maximizing small biopsy patient samples: unified RNA-seq platform assessment of over 120,000 patient biopsies","volume":"13","author":"Walsh","year":"2022","journal-title":"J Pers Med"},{"key":"2026070909444917200_bib52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/thy.2019.0490","article-title":"A thyroid genetic classifier correctly predicts benign nodules with indeterminate cytology: two independent, multicenter, prospective validation trials","volume":"30","author":"Zafereo","year":"2020","journal-title":"Thyroid"},{"key":"2026070909444917200_bib53","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0409","article-title":"ThyroidPrint\u00ae: clinical utility for indeterminate thyroid cytology","volume":"30","author":"Olmos","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070909444917200_bib54","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1089\/thy.2018.0254","article-title":"Molecular classification of thyroid nodules with indeterminate cytology: development and validation of a highly sensitive and specific new miRNA-Based classifier test using fine-needle aspiration smear slides","volume":"28","author":"Santos","year":"2018","journal-title":"Thyroid"},{"key":"2026070909444917200_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104137","article-title":"Clinical decision support analysis of a microRNA-based thyroid molecular classifier: a real-world, prospective and multicentre validation study","volume":"82","author":"Santos","year":"2022","journal-title":"EBioMedicine"},{"key":"2026070909444917200_bib56","doi-asserted-by":"crossref","first-page":"E1719","DOI":"10.1210\/jc.2011-0459","article-title":"Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules","volume":"96","author":"Li","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib57","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1210\/clinem\/dgae355","article-title":"Publicly funded molecular testing of indeterminate thyroid nodules: Canada\u2019s experience","volume":"110","author":"L\u00e9vesque","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070909444917200_bib58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00268-019-05177-7","article-title":"Selective use of molecular testing based on sonographic features of cytologically indeterminate thyroid nodules: a decision analysis","volume":"44","author":"Zanocco","year":"2020","journal-title":"World J Surg"},{"key":"2026070909444917200_bib59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/thy.2018.0779","article-title":"Molecular testing versus diagnostic lobectomy in Bethesda III\/IV thyroid nodules: a cost-effectiveness analysis","volume":"29","author":"Nicholson","year":"2019","journal-title":"Thyroid"},{"key":"2026070909444917200_bib60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.surg.2017.10.004","article-title":"Cost-effectiveness of lobectomy versus genetic testing (Afirma(R)) for indeterminate thyroid nodules: considering the costs of surveillance","volume":"163","author":"Balentine","year":"2018","journal-title":"Surgery"},{"key":"2026070909444917200_bib61","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0194599817725709","article-title":"Cost-effectiveness of gene expression classifier testing of indeterminate thyroid nodules utilizing a real cohort comparator","volume":"157","author":"Shapiro","year":"2017","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/2\/ERC-25-0258.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/2\/ERC-25-0258.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0258\/505780\/erc-25-0258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0258\/505780\/erc-25-0258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:45:02Z","timestamp":1783604702000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/2\/e250258\/75538\/Molecular-testing-for-the-management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0258","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"e250258"}}